[go: up one dir, main page]

WO2010057242A3 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO2010057242A3
WO2010057242A3 PCT/AT2009/000452 AT2009000452W WO2010057242A3 WO 2010057242 A3 WO2010057242 A3 WO 2010057242A3 AT 2009000452 W AT2009000452 W AT 2009000452W WO 2010057242 A3 WO2010057242 A3 WO 2010057242A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
vaccine
acid sequence
amino acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2009/000452
Other languages
German (de)
English (en)
Other versions
WO2010057242A2 (fr
Inventor
Sylvia Brunner
Pola Linzmayer-Hirt
Walter Schmidt
Bettina Wanko
Gabriele Winsauer
Christina Woess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of WO2010057242A2 publication Critical patent/WO2010057242A2/fr
Publication of WO2010057242A3 publication Critical patent/WO2010057242A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vaccin comportant au moins un peptide dérivé de la séquence d'acide aminé TLGTNFGRCVDLFAPGEDII- GASSDCSTCFVSQSGTSQAAAHVAGIA (SÉQ ID N°1) et présentant une longueur minimale de 7 acides aminés, le peptide comportant également la séquence d'acide aminé DIIGA (SÉQ ID N°2) et/ou CFVSQSG (SÉQ ID N°3) de la SÉQ ID Nr. 1.
PCT/AT2009/000452 2008-11-19 2009-11-19 Vaccin Ceased WO2010057242A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1800/2008 2008-11-19
AT0180008A AT507604A1 (de) 2008-11-19 2008-11-19 Behandlung von atherosklerose

Publications (2)

Publication Number Publication Date
WO2010057242A2 WO2010057242A2 (fr) 2010-05-27
WO2010057242A3 true WO2010057242A3 (fr) 2010-09-16

Family

ID=42026338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2009/000452 Ceased WO2010057242A2 (fr) 2008-11-19 2009-11-19 Vaccin

Country Status (2)

Country Link
AT (1) AT507604A1 (fr)
WO (1) WO2010057242A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
EP2450382A1 (fr) * 2010-11-04 2012-05-09 Affiris AG Peptide immunogène
EP2532359A1 (fr) 2011-06-10 2012-12-12 Affiris AG Fragments de CETP
DK2570135T3 (en) 2011-09-13 2016-02-15 Affiris Ag PCSK9-Vaccine
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
WO2016119067A1 (fr) * 2015-01-30 2016-08-04 Pronasci Inc. Peptides dérivés du domaine catalytique du gène pcsk9 humain et utilisations de ceux-ci pour favoriser l'activité du récepteur des ldl

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063382A2 (fr) * 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonistes de pcsk9
WO2008105797A2 (fr) * 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucléotides codant pour de nouveaux variants du pcsk9
WO2008125623A2 (fr) * 2007-04-13 2008-10-23 Novartis Ag Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105797A2 (fr) * 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucléotides codant pour de nouveaux variants du pcsk9
WO2008063382A2 (fr) * 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonistes de pcsk9
WO2008125623A2 (fr) * 2007-04-13 2008-10-23 Novartis Ag Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOUTAR ANNE K ET AL: "Mechanisms of disease: genetic causes of familial hypercholesterolemia", NATURE CLINICAL PRACTICE. CARDIOVASCULAR MEDICINE, NATURE PUBLISHING GROUP, GB, vol. 4, no. 4, 1 April 2007 (2007-04-01), pages 214 - 225, XP009131428, ISSN: 1743-4300 *
WANG L-F ET AL: "EPITOPE IDENTIFICATION AND DISCOVERY USING PHAGE DISPLAY LIBRARIES: APPLICATIONS IN VACCINE DEVELOPMENT AND DIAGNOSTICS", CURRENT DRUG TARGETS, BENTHAM SCIENCE PUBLISHER, US, vol. 5, no. 1, 1 January 2004 (2004-01-01), pages 1 - 15, XP009047802, ISSN: 1389-4501 *

Also Published As

Publication number Publication date
AT507604A1 (de) 2010-06-15
WO2010057242A2 (fr) 2010-05-27

Similar Documents

Publication Publication Date Title
IN2014CN02050A (fr)
NZ600690A (en) Fkbp-l and uses thereof
MX2011011960A (es) Peptidos penetradores de celulas.
EP2455459A3 (fr) Variantes de lipase pour utilisation pharmaceutique
WO2010057242A3 (fr) Vaccin
UA111141C2 (uk) Рекомбінантні антигени рсв
WO2008009437A3 (fr) Acides nucléiques de liaison à sdf-i
WO2009087082A3 (fr) Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
MX2010001856A (es) Proteina.
WO2008113536A8 (fr) Peptides neurotrophiques
MX2010003109A (es) Acidos nucleicos de enlace c5a.
WO2007093409A3 (fr) Acides nucleiques se liant au mcp-i
WO2007107587A3 (fr) Hydrolysats proteiques hypocholestérolémiants
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2008066816A3 (fr) Procédés de préparation de peptides, de protéines et de glucides fonctionnalisés et de leurs conjugués
WO2008047370A3 (fr) Compositions et méthodes permettant d'induire l'angiogenèse
WO2008087224A3 (fr) Netrine 4 mutée, fragments de cette dernière et utilisations comme médicament
WO2010026219A3 (fr) Nouveaux facteurs de réponse à l’éthylène de la tomate et leurs utilisations
CY1111630T1 (el) Παραγωγα κυτοκινων
WO2010103515A3 (fr) Compositions et procédés pour la prévention et le traitement de maladies neurodégénératives
WO2009148229A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph
WO2007029262A3 (fr) Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus
WO2009148230A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph
WO2012031103A3 (fr) Inhibiteurs de bcl-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09768321

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09768321

Country of ref document: EP

Kind code of ref document: A2